Geron Corporation ( GERN ) now has five full quarters of the Rytelo (imetelstat) launch behind it, but the launch isn't going from strength to strength. In August, I rated GERN a buy, noting aScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure:I/we have no stock, option or similar derivati ...